• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease.α-1抗胰蛋白酶治疗类固醇难治性急性移植物抗宿主病的经验
Indian J Hematol Blood Transfus. 2022 Jul;38(3):601-605. doi: 10.1007/s12288-022-01524-2. Epub 2022 Feb 7.
2
α-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.α-1 抗胰蛋白酶输注治疗激素耐药性急性移植物抗宿主病。
Blood. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746. Epub 2018 Feb 2.
3
Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.维多珠单抗用于类固醇难治性胃肠道晚期急性移植物抗宿主病的二线治疗。
Ther Adv Hematol. 2024 Sep 6;15:20406207241276982. doi: 10.1177/20406207241276982. eCollection 2024.
4
Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.异体造血干细胞移植后多药耐药的急性和晚期移植物抗宿主病的间充质基质细胞治疗的安全性和有效性。
Ann Hematol. 2023 Jun;102(6):1537-1547. doi: 10.1007/s00277-023-05216-3. Epub 2023 Apr 17.
5
Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.异体造血干细胞移植后高度难治性急性胃肠道移植物抗宿主病应用维得利珠单抗：单中心儿科系列研究。
Adv Clin Exp Med. 2022 Mar;31(3):345-350. doi: 10.17219/acem/146321.
6
Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.同种异体人间质干细胞治疗（remestemcel-L，Prochymal）作为儿科患者严重难治性急性移植物抗宿主病的挽救治疗药物。
Biol Blood Marrow Transplant. 2014 Feb;20(2):229-35. doi: 10.1016/j.bbmt.2013.11.001. Epub 2013 Nov 8.
7
Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease.人源 α1-抗胰蛋白酶在重度预处理的激素耐药性胃肠移植物抗宿主病患者中仍然有效。
Biol Blood Marrow Transplant. 2020 Sep;26(9):1620-1626. doi: 10.1016/j.bbmt.2020.05.014. Epub 2020 May 25.
8
[Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].[抗CD(25)单克隆抗体作为80例接受异基因造血干细胞移植的类固醇难治性急性移植物抗宿主病的挽救治疗]
Zhonghua Nei Ke Za Zhi. 2018 May 1;57(5):324-329. doi: 10.3760/cma.j.issn.0578-1426.2018.05.004.
9
Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.巴利昔单抗治疗亲缘单倍体造血干细胞移植后儿童患者激素耐药性急性移植物抗宿主病。
Biol Blood Marrow Transplant. 2020 Feb;26(2):351-357. doi: 10.1016/j.bbmt.2019.10.031. Epub 2019 Nov 5.
10
Clinical Features, Treatment, and Outcome of Pediatric Steroid Refractory Acute Graft-Versus-Host Disease: A Multicenter Study.儿科类固醇难治性急性移植物抗宿主病的临床特征、治疗和转归：一项多中心研究。
Transplant Cell Ther. 2022 Sep;28(9):600.e1-600.e9. doi: 10.1016/j.jtct.2022.06.008. Epub 2022 Jun 16.

本文引用的文献

1
Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease.人源 α1-抗胰蛋白酶在重度预处理的激素耐药性胃肠移植物抗宿主病患者中仍然有效。
Biol Blood Marrow Transplant. 2020 Sep;26(9):1620-1626. doi: 10.1016/j.bbmt.2020.05.014. Epub 2020 May 25.
2
α-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.α-1 抗胰蛋白酶输注治疗激素耐药性急性移植物抗宿主病。
Blood. 2018 Mar 22;131(12):1372-1379. doi: 10.1182/blood-2017-11-815746. Epub 2018 Feb 2.
3
Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease.
Am J Hematol. 2017 Oct;92(10):E610-E611. doi: 10.1002/ajh.24850. Epub 2017 Jul 29.
4
Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease.贝林妥欧单抗治疗类固醇难治性急性移植物抗宿主病的 1 期多中心试验。
Blood. 2017 Jun 15;129(24):3256-3261. doi: 10.1182/blood-2017-03-772210. Epub 2017 May 4.
5
Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.类固醇难治性急性移植物抗宿主病对α1-抗胰蛋白酶的反应
Biol Blood Marrow Transplant. 2016 Sep;22(9):1596-1601. doi: 10.1016/j.bbmt.2016.05.011. Epub 2016 May 17.
6
Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease.粪便钙卫蛋白和α-1 抗胰蛋白酶可预测胃肠道移植物抗宿主病的严重程度和对皮质类固醇的反应。
Blood. 2012 Jun 14;119(24):5909-17. doi: 10.1182/blood-2011-12-397968. Epub 2012 May 3.
7
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.急性移植物抗宿主病的一线和二线全身治疗：美国血液和骨髓移植学会的建议。
Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63. doi: 10.1016/j.bbmt.2012.04.005. Epub 2012 Apr 14.
8
Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.α-1 抗胰蛋白酶单药疗法可降低实验性异基因骨髓移植后的移植物抗宿主病。
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):564-9. doi: 10.1073/pnas.1117665109. Epub 2011 Dec 27.
9
Graft-versus-host disease treatment: predictors of survival.移植物抗宿主病治疗：生存预测因素。
Biol Blood Marrow Transplant. 2010 Dec;16(12):1693-9. doi: 10.1016/j.bbmt.2010.05.019. Epub 2010 Jun 9.
10
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.443例患者对作为急性移植物抗宿主病主要治疗方法的类固醇的反应：分级系统比较
Biol Blood Marrow Transplant. 2002;8(7):387-94. doi: 10.1053/bbmt.2002.v8.pm12171485.

α-1抗胰蛋白酶治疗类固醇难治性急性移植物抗宿主病的经验

Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease.

作者信息

Koyun Derya, Seval Güldane Cengiz, Kırcalı Ekin, Bozdağ Sinem Civriz, Toprak Selami Koçak, Topçuoğlu Pervin, Özcan Muhit, Arslan Önder, Demirer Taner, İlhan Osman, Beksaç Meral, Gürman Günhan, Yüksel Meltem Kurt

机构信息

Ankara University School of Medicine, Hematology Department, Ankara, Turkey.

出版信息

Indian J Hematol Blood Transfus. 2022 Jul;38(3):601-605. doi: 10.1007/s12288-022-01524-2. Epub 2022 Feb 7.

DOI:10.1007/s12288-022-01524-2
PMID:35747565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9209553/
Abstract

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) treatment has a low response rate and a high risk of infection in allogeneic hematopoietic stem cell transplantation. The standard approach to be applied in this situation is uncertain. This study aims to evaluate the effectiveness and safety of alpha-1-antitrypsin (AAT). In the study, the results of five SR-aGVHD patients received AAT evaluated. Complete response was seen 2 of four patients with gastrointestinal (GI) aGVHD, partial response in one GI and one liver aGVHD. The overall response rate was 80%. AAT is an effective and safe treatment option in SR-aGVHD.

摘要

在异基因造血干细胞移植中，类固醇难治性急性移植物抗宿主病（SR-aGVHD）的治疗缓解率低且感染风险高。在这种情况下应用的标准方法尚不确定。本研究旨在评估α-1抗胰蛋白酶（AAT）的有效性和安全性。在该研究中，对5例接受AAT治疗的SR-aGVHD患者的结果进行了评估。4例胃肠道（GI）aGVHD患者中有2例出现完全缓解，1例GI aGVHD和1例肝脏aGVHD患者出现部分缓解。总缓解率为80%。AAT是SR-aGVHD一种有效且安全的治疗选择。